Dexamethasone

Catalog No.S1322 Batch:S132204

Print

Technical Data

Formula

C22H29FO5
Molecular Weight 392.46 CAS No. 50-02-2
Solubility (25°C)* In vitro DMSO 78 mg/mL (198.74 mM)
Ethanol 11 mg/mL (28.02 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.
Targets
interleukin receptor [1]
(Cell-free assay)
In vitro

Dexamethasone results in decrease in transmonolayer paracellular permeability mainly to sucrose, fluorescein and dextrans of up to 20 KDa in an immortalised rat brain endothelial cell line (GPNT). Dexamethasone results in filamentous actin and the cytoskeleton associated protein cortactin being highly concentrated in the regions of cell-cell contact with few F-actin stress fibres visible within the cytoplasm in cultured rat brain endothelial cells, an observation consistent with a more differentiated barrier phenotype induced by dexamethasone. Dexamethasone treatment has been shown to strongly stimulate the level of the Id-1 protein, which is a serum-inducible helix-loop-helix transcriptional repressor, involved in cell differentiation, and this effect was shown to be associated with reorganisation of ZO-1 to the cell periphery in Con8 mammary epithelial tumor cells. Dexamethasone prevents cytokine-induced enhanced expression of MMP-9 and alterations in the expression of ZO-1 in untreated GPNT monolayers. [1]

Dexamethasone depletes both basal and TNF-alpha-stimulated GSH levels by down-regulating the gamma-GCS-heavy subunit transcription via a mechanism involving AP-1 (c-Jun) in alveolar epithelial cells. Dexamethasone decreases both basal and stimulated GSH levels (TNF-α-treated) in alveolar epithelial cells (A549), without any change in GSSG. [2]
In vivo

Dexamethasone is administered i.m. to pregnant ewes, leads to the following results (1) blood pressure is unchanged; (2) as previously reported in the fetus, sensitivity to endothelin-1 (ET) is increased; (3) acetylcholine-induced relaxation is increased; (4) L-NAME suppressible vasodilatory response to ET is abolished; (5) there is no change in endothelium-independent vasodilatation; and (6) there is no change in eNOS RNA and protein levels, when compared to saline treated controls. [3]

Protocol (from reference)

Cell Assay:

[6]
  • Cell lines

    CB CD34+ cells

  • Concentrations

    1 μM

  • Incubation Time

    16 h

  • Method

    Cells were treated with indicated concentrations of drug.
Animal Study:

[7]
  • Animal Models

    Mice

  • Dosages

    1 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/12782340/
  • https://pubmed.ncbi.nlm.nih.gov/11007940/
  • https://pubmed.ncbi.nlm.nih.gov/12562957/
  • https://pubmed.ncbi.nlm.nih.gov/16166452/
  • https://pubmed.ncbi.nlm.nih.gov/17440100/
  • https://pubmed.ncbi.nlm.nih.gov/28263313/
  • https://pubmed.ncbi.nlm.nih.gov/35544603/

Customer Product Validation

<p>Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments.</p>

Data from [ Oncogene , 2013 , 32, 1316-29 ]

<p>(d) BT549 cells were treated and analyzed by immunofluorescence microscopy as in Figure b. (e) BT549 cells were treated as described in Figure b and analyzed for invasion as in Figure 3c. (f) Quantitation of junctional E-cadherin staining of the indicated cell lines treated with DMSO vehicle or Dex.+ Larg. as described in Figure b. Results are presented as the mean of analyses of three different fields of cells for each sample±s.d. Statistical significance was assessed using Student’s t -test.</p>

Data from [ Oncogene , 2013 , 32, 1316-29 ]

Effect of SENP2 overexpression on apoptosis-related proteins in CLL cells with or without dexamethasone treatment. (A and B) MEC2 cells in which SENP2 was overexpressed and the control cells were cultured in 6 cm dishes and then treated with dexamethasone for 24 h after reaching 70% confluence. Western blot analysis was then performed to inspect the expression levels of cleaved caspase-9, caspase-9, cleaved caspase-3, caspase-3, c-Myc, p53, Bax and Bcl-2 in these cells. GAPDH was used to confirm equal amount of proteins loaded in each lane. CLL, chronic lymphocytic leukemia; NC-OE-SENP2, MEC2 cells transfected with null (control) overexpression vector; OE-SENP2, MEC2 cells transfected with SENP2 overexpression vector; NC-shRNA-SENP2, MEC2 cells transfected with null control shRNA; shRNA-SENP2, MEC2 cells transfected with shRNA against SENP2; +, dexamethasone treatment, −, no dexamethasone treatment.

Data from [ , , Int J Oncol, 2018, doi:10.3892/ijo.2018.4635 ]

Selleck's Dexamethasone Has Been Cited by 136 Publications

Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL [ Signal Transduct Target Ther, 2025, 10(1):230] PubMed: 40695793
The ESCRT protein CHMP5 promotes T cell leukemia by enabling BRD4-p300-dependent transcription [ Nat Commun, 2025, 16(1):4133] PubMed: 40319015
Blocking the SIRPα-CD47 axis promotes macrophage phagocytosis of exosomes derived from visceral adipose tissue and improves inflammation and metabolism in mice [ J Biomed Sci, 2025, 32(1):31] PubMed: 40016734
Aurantio-obtusin modulates Wilms Tumour 1 within the breast tumour microenvironment reducing immunosuppression and tumour growth [ Cell Commun Signal, 2025, 23(1):309] PubMed: 40598415
Glucocorticoid receptor inhibits Th2 immune responses by down-regulating Pparg and Gata3 in schistosomiasis [ Front Immunol, 2025, 16:1518586] PubMed: 40196108
Silybin attenuates microglia-mediated neuroinflammation via inhibition of STING in experimental subarachnoid hemorrhage [ Int Immunopharmacol, 2025, 151:114305] PubMed: 39986195
Distinct effects of glucocorticoid on pseudorabies virus infection in neuron-like and epithelial cells [ J Virol, 2025, 99(2):e0147224] PubMed: 39853115
Effect of Sceptridium ternatum extract (STE) on radiation-induced pulmonary fibrosis by inhibiting cell adhesion factor CEACAM1 [ J Ethnopharmacol, 2025, 345:119550] PubMed: 40015535
Insulin-Like Growth Factor 2 Reverses Synaptic and Cognitive Deficits in Fetal Growth Restriction Mice [ FASEB J, 2025, 39(11):e70691] PubMed: 40458983
Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection [ Life Sci Alliance, 2025, 8(7)e202402837] PubMed: 40262853

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.